TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer
TriSalus Life Sciences announced a virtual KOL event on June 24 to discuss new real-world evidence for its Pressure-Enabled Drug Delivery (PEDD) technology in liver cancer. A newly published study showed that PEDD delivered a 48% improvement in drug delivery to target tumors and reduced hospital readmissions by 61% compared to conventional embolization. Dr.
Key figures
- Drug delivery improvement
- 48%
- Annual liver tumor diagnoses
- 900,000
- Hospital readmission reduction
- 61%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.